Moderna Receives Price Target Hike and FDA Panel Nod for Flu Vaccine

Key Facts

1Piper Sandler reiterated an Overweight rating on Moderna and raised its price target to $77.00.

2Moderna's seasonal flu vaccine mFlusiva received a unanimous 9-0 endorsement from an FDA advisory panel.

3Moderna is expanding its research pipeline into new cancer treatments and autoimmune diseases using its mRNA platform.

4Moderna's stock rose 10.84% to $66.23 on the day.

As Moderna works to diversify beyond COVID-19 vaccines, the company received a dual boost from analysts and regulators. Piper Sandler reiterated an Overweight rating and raised its price target to $77, while an FDA advisory panel unanimously voted 9-0 to endorse the seasonal flu vaccine mFlusiva. Moderna's stock jumped 10.84% to close at $66.23 on the day.

The positive catalyst follows a period of pressure on the stock due to waning demand for COVID shots. Before the news, MRNA closed at $59.75 on June 25, 2026 (per market data), with a daily range of $57.91–$61.86. The company is also expanding its pipeline into cancer treatments and autoimmune diseases using its mRNA platform, bolstering longer-term growth prospects.

With the stock at $66.23, the new $77 price target implies roughly 16% upside from current levels. Investors will watch for formal FDA approval of mFlusiva and updates on oncology and autoimmune trials. No major economic releases are expected in the near term that would directly affect the stock, though sector quarterly earnings may provide additional context.